[{"Physician_Profile_ID": "5433", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "82.60", "Date_of_Payment": "08/26/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106113532", "Name_of_Associated_Covered_Drug_or_Biological1": "Metformin", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Add-on metformin study with active comparator to Januvia  2nd head-to-head study against Januvia", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "5433", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "70.80", "Date_of_Payment": "12/22/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106113519", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy & Safety of Daily Oral TAK-875 25 mg & 50 mg Compared to Placebo When Used in Combination with Sitagliptin", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "5433", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "59.00", "Date_of_Payment": "12/22/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106113503", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Multicenter, Randomized, DB, Placebo-Controlled, P3 Study to Evaluate CV Outcomes of TAK-875, 50 mg in Addition to SOC in Subjects with T2DM and with CV Disease or Multiple Risk Factors for CV Events", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "5433", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "35.40", "Date_of_Payment": "11/21/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106113517", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Placebo controlled, Doubled Blind Parallel-Group study to evaluate the Glycemic effects and safety of 25 mg BID and 50 mg QD of TAK-875 on HbA1c reduction and other measures of glycemic control", "Research_Information_Link": "", "Context_of_Research": ""}]